E Standl

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons
    Eberhard Standl
    Munich Diabetes Research Group e V, Munich Helmholtz Centre, Ingolstaedter Landstrasse 1, Munich Neuherberg, Germany
    Diabetes Metab Res Rev 28:60-6. 2012
  2. ncbi Dysglycemia and abdominal obesity
    Eberhard Standl
    Munich Diabetes Research Group, Helmholtz Centre Munich Neuherberg, Ingolstaedter Landstrasse 1, D 85764 Neuherberg, Germany
    Curr Vasc Pharmacol 10:678-9. 2012
  3. ncbi Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation
    Eberhard Standl
    Munich Diabetes Research Group, Helmholtz Centre Munich Neuherberg, Germany
    Diab Vasc Dis Res 9:163-9. 2012
  4. ncbi Postprandial hyperglycemia and glycemic variability: should we care?
    Eberhard Standl
    Munich Diabetes Research Institute, Munich Helmholtz Centre, Munich, Germany
    Diabetes Care 34:S120-7. 2011
  5. ncbi Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Eberhard Standl
    Munich Diabetes Research Institute, Kölner Pl 1, D 80804 Munich, Germany
    Diabetes Care 31:S136-9. 2008
  6. ncbi The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus
    E Standl
    Diabetes Research Institute Munich, Kolner Platz 1, 80804 Munich, Germany
    Diabetologia 46:M30-6. 2003
  7. ncbi Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility
    E Standl
    Munich Institute of Diabetes Research and 3 Medical Department, Krankenhaus München Schwabing, Munich, Germany
    Horm Metab Res 38:172-7. 2006
  8. ncbi The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes
    Eberhard Standl
    Diabetes Research Institute, Munich, Germany
    Diabetes Technol Ther 6:579-88. 2004
  9. ncbi Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride
    Eberhard Standl
    Munich Diabetes Research Institute, 3 Medical Department, , , D-80804, , Germany
    Diabetes Care 28:419-20. 2005
  10. ncbi [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)]
    E Standl
    , , 85764, , Germany
    Internist (Berl) 48:1173-6. 2007

Detail Information

Publications52

  1. ncbi What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons
    Eberhard Standl
    Munich Diabetes Research Group e V, Munich Helmholtz Centre, Ingolstaedter Landstrasse 1, Munich Neuherberg, Germany
    Diabetes Metab Res Rev 28:60-6. 2012
    ..Awareness of these facts and highly individualized therapy seem to be the way forward...
  2. ncbi Dysglycemia and abdominal obesity
    Eberhard Standl
    Munich Diabetes Research Group, Helmholtz Centre Munich Neuherberg, Ingolstaedter Landstrasse 1, D 85764 Neuherberg, Germany
    Curr Vasc Pharmacol 10:678-9. 2012
    ..In addition, the multiple effects of insulin also on the regulation of the vasculature are shifted towards vasoconstriction and proliferation in the context of insulin resistance and the excessively high levels...
  3. ncbi Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation
    Eberhard Standl
    Munich Diabetes Research Group, Helmholtz Centre Munich Neuherberg, Germany
    Diab Vasc Dis Res 9:163-9. 2012
    ..The ultimate determination of the cardiovascular effects of alpha-glucosidase inhibitors in terms of clinical outcomes awaits the results of ongoing long-term, randomised, placebo-controlled trials...
  4. ncbi Postprandial hyperglycemia and glycemic variability: should we care?
    Eberhard Standl
    Munich Diabetes Research Institute, Munich Helmholtz Centre, Munich, Germany
    Diabetes Care 34:S120-7. 2011
    ..e., that we should care about postprandial hyperglycemia and glycemic variability. The absence of a uniformly accepted standard of how to estimate these parameters adds a further challenge to this whole debate...
  5. ncbi Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Eberhard Standl
    Munich Diabetes Research Institute, Kölner Pl 1, D 80804 Munich, Germany
    Diabetes Care 31:S136-9. 2008
  6. ncbi The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus
    E Standl
    Diabetes Research Institute Munich, Kolner Platz 1, 80804 Munich, Germany
    Diabetologia 46:M30-6. 2003
    ..Additional substantiation of their long-term effect on improving life expectancy and reducing diabetic complications in Type II diabetic patients is now required...
  7. ncbi Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility
    E Standl
    Munich Institute of Diabetes Research and 3 Medical Department, Krankenhaus München Schwabing, Munich, Germany
    Horm Metab Res 38:172-7. 2006
    ..To compare the incidence of nocturnal hypoglycemia and glycemic control following bedtime or morning insulin glargine (LANTUS; glargine) plus glimepiride...
  8. ncbi The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes
    Eberhard Standl
    Diabetes Research Institute, Munich, Germany
    Diabetes Technol Ther 6:579-88. 2004
    ..This trial compared the long-term safety and efficacy of the basal insulin preparations, insulin detemir and NPH insulin, in basal-bolus therapy for patients with type 1 diabetes...
  9. ncbi Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride
    Eberhard Standl
    Munich Diabetes Research Institute, 3 Medical Department, , , D-80804, , Germany
    Diabetes Care 28:419-20. 2005
  10. ncbi [Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)]
    E Standl
    , , 85764, , Germany
    Internist (Berl) 48:1173-6. 2007
  11. ncbi The impact of glucose-lowering therapy on cardiovascular outcomes
    Eberhard Standl
    Munich Diabetes Research Institute at the Munich Helmholtz Center, Munich Neuherberg, Germany
    Best Pract Res Clin Endocrinol Metab 23:401-11. 2009
    ..5%, which takes time to tailor (poly-)pharmacotherapy gently to the patient's needs. Drug-specific effects, both advantageous and disadvantageous, of blood-glucose-lowering therapy cannot be excluded currently and warrant further studies...
  12. ncbi Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy
    O Schnell
    Diabetes Research Institute, Munich, Germany
    Diabetes Obes Metab 9:853-8. 2007
    ....
  13. ncbi Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics
    E Standl
    Schwabing Hospital, Koelner Platz 1, D-80804 Munich, Germany
    Diabetes Res Clin Pract 51:205-13. 2001
    ..No cases of hypoglycaemia were reported. CONCLUSIONS: Miglitol can safely and effectively be added to long-term combination therapy in people with Type 2 diabetes inadequately controlled with glibenclamide plus metformin...
  14. ncbi Chromium in metabolic and cardiovascular disease
    M Hummel
    Diabetes Research Institute and Academical Hospital Munich Schwabing, Munich, Germany
    Horm Metab Res 39:743-51. 2007
    ..The existing data suggest to concentrate future studies on certain forms as chromium picolinate and doses as at least 200 mcg per day...
  15. ncbi Successful treatment with insulin analog lispro in IDDM with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion. A case report
    M Meier
    Diabetes Research Institute, Schwabing Hospital, Munich, Germany
    Diabetes Care 21:1044-5. 1998
    ....
  16. ncbi Two Caucasian families with the hepatocyte nuclear factor-1alpha mutation Tyr218Cys
    M Hummel
    Diabetes Research Institute and Academical Hospital Munich Schwabing, Munich, Germany
    Exp Clin Endocrinol Diabetes 115:62-4. 2007
    ..Clinical and laboratory examinations are shown in detail. Patients with HNF-1alpha related MODY may develop the full spectrum of diabetic complications. Therefore, early detection of family members with MODY3 is warranted...
  17. ncbi Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
    M Füchtenbusch
    Department of Endocrinology, Diabetology and Gastroenterology, Academic Hospital München Schwabing, Munich, Germany
    Exp Clin Endocrinol Diabetes 111:288-93. 2003
    ..Here, autoimmune panniculitis appears to be an associated feature of the APECED syndrome. Our findings support the use of immunosuppressive therapy for autoimmune disease components of the APECED syndrome...
  18. ncbi Semi-automatic generation of medical tele-expert opinion for primary care physician
    E Biermann
    Institut fur Diabetesforschung, Kölnerplatz 1, D 80804 München, Germany
    Methods Inf Med 42:212-9. 2003
    ..A computer-based system has been developed for the generation of medical expert opinions on the insulin-resistance syndrome, based on clinical data obtained from primary care physicians...
  19. ncbi [Cardiovascular risk in diabetes--diagnostic and therapeutic aspects]
    O Schnell
    Institut fur Diabetesforschung, 3 Med Klinik, Krankenhaus München Schwabing
    MMW Fortschr Med 146:36-8. 2004
    ..An example of a successful approach for metabolic intervention is glucose-insulin infusion to optimize the metabolic condition during the acute phase...
  20. ncbi How would patients behave if they were continually informed of their blood glucose levels? A simulation study using a "virtual" patient
    Eberhard Biermann
    Staedtisches Klinikum Muenchen GmbH, Klinikum Schwabing, Muenchen, Germany
    Diabetes Technol Ther 10:178-87. 2008
    ..In this study, we use a computer-generated "virtual" patient to predict changes in behavior that may result from an increased awareness of BG levels...
  21. ncbi Cardiac sympathetic dysinnervation in Type 2 diabetes mellitus with and without ECG-based cardiac autonomic neuropathy
    Oliver Schnell
    Diabetes Research Institute, Third Medical Department, Academic Schwabing City Hospital, Munich, Germany
    J Diabetes Complications 16:220-7. 2002
    ..In Type 2 diabetes mellitus, the posterior myocardium is predominantly affected and the extent of dysinnervation is more pronounced in the presence of ECG-based cardiac autonomic neuropathy...
  22. ncbi Are there time and cost savings by using telemanagement for patients on intensified insulin therapy? A randomised, controlled trial
    Eberhard Biermann
    Institute for Diabetes Research, Kolner Platz 1, 80804 Munich, Germany
    Comput Methods Programs Biomed 69:137-46. 2002
    ..This study focuses on the fiscal and administrative aspects of telemanagement, which was used to establish a supervised autonomy of patients on intensified insulin therapy...
  23. ncbi Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction: the Munich registry
    Oliver Schnell
    Diabetes Research Institute, and Third Medical Clinic, Academic Schwabing Hospital, Munich, Germany
    Diabetes Care 27:455-60. 2004
    ..The aim of this study was to improve quality care management and to compare hospital mortality and therapeutic approaches (i.e., PTCA, stenting, GPIIb/IIIa receptor antagonists, glucose-insulin infusion)...
  24. ncbi [Insulin therapy improves cardiac autonomic function in type 2 diabetic patients]
    Oliver Schnell
    3 Medizinische Abteilung KH München Schwabing und Institut für Diabetesforschung, Munchen
    Herz 29:519-23. 2004
    ..There is scintigraphic evidence that insulin improves cardiac autonomic innervation in diabetic patients. The aim of the study was to assess the effects of insulin therapy on parameters of cardiac reflex tests in type 2 diabetic patients...
  25. ncbi Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects
    E Standl
    Munich Diabetes Research Institute, Germany
    Diabetes Metab 29:6S121-2. 2003
    ....
  26. ncbi Autoantibodies against autonomic nervous tissues in type 2 diabetes mellitus: no association with cardiac autonomic dysfunction
    O Schnell
    Diabetes Research Institute, Munich, Germany
    Exp Clin Endocrinol Diabetes 108:181-6. 2000
    ..In Type 2 DM, CF-SG and CF-PSG autoantibodies are not frequently observed. The results do not give evidence, that immunological factors--like in Type 1 DM--play a role in the pathogenesis of cardiac autonomic dysfunction in Type 2 DM...
  27. ncbi Coronary calcification in long-term type 1 diabetic patients -- a study with multi slice spiral computed tomography
    C Thilo
    , Medical Hospital I, Grosshadern, Munich, Germany
    Exp Clin Endocrinol Diabetes 112:561-5. 2004
    ..MSCT is a promising non-invasive approach to analyze early alterations of the coronary system in diabetic patients...
  28. ncbi QTc interval and scintigraphically assessed myocardial perfusion in newly diagnosed and long-term type 1 diabetes mellitus
    M Meier
    Third Medical Department, Schwabing City Hospital, Munich, Germany
    J Diabetes Complications 14:90-5. 2000
    ..Future investigations are required to analyze the role of QTc interval in the pathogenesis of abnormalities of myocardial perfusion...
  29. ncbi C-reactive protein in diabetic and nondiabetic patients with acute myocardial infarction
    Wolfgang Otter
    Cardiology, Academical Teaching Hospital, Schwabing, Munich, Germany
    Diabetes Care 30:3080-2. 2007
  30. ncbi [62 year-old patient with rapid progressive edema, low potassium and hypertension]
    M Hummel
    Medizinische Klinik 3, Krankenhaus München Schwabing, Munich, Germany
    Internist (Berl) 47:427, 429-33. 2006
    ..A Sertoli-cell-tumor of the testis was diagnosed as an additional carcinoma. Palliative chemotherapy and adrenostatic agents did not improve the clinical findings and the patient died eight weeks after admission...
  31. ncbi Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus
    W Otter
    Department of Cardiology, Schwabing City Hospital and Diabetes Research Institute, Munich, Germany
    Diabet Med 21:183-7. 2004
    ..To assess hospital mortality and morbidity in diabetic and non-diabetic patients with acute myocardial infarction and to compare the results between the two groups...
  32. ncbi The Munich Myocardial Infarction Registry: impact of C-reactive protein and kidney function on hospital mortality in diabetic patients
    Oliver Schnell
    Diabetes Research Institute, Helmholtz Center, Ingolstadter Landstrasse 1, 85764 Neuherberg, Germany
    Diab Vasc Dis Res 7:225-30. 2010
    ..The aim of this study was to analyse hospital mortality with regards to the presence of diabetes, elevation of C-reactive protein (CRP) levels and impaired kidney function (IKF) on admission...
  33. ncbi Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
    John A Dormandy
    Department of Clinical Vascular Research, Ingelby House, St Georges Hospital, Blackshaw Road, London SW17 0QT, UK
    Lancet 366:1279-89. 2005
    ..Our aim, therefore, was to ascertain whether pioglitazone reduces macrovascular morbidity and mortality in high-risk patients with type 2 diabetes...
  34. ncbi Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart
    Matteo Anselmino
    Department of Cardiology, San Giovanni Battista Molinette Hospital, Turin 10126, Italy
    Eur Heart J 29:177-84. 2008
    ..This report from the Euro Heart Survey on Diabetes and the Heart describes present practice in relation to 1 year prognosis...
  35. ncbi The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart
    Małgorzata Bartnik
    Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden
    Eur Heart J 25:1880-90. 2004
    ..The objective behind the Euro Heart Survey on diabetes and the heart was to study the prevalence of abnormal glucose regulation in adult patients with coronary artery disease (CAD)...
  36. ncbi [Reduction of cardiovascular risk--a new approach in therapy of type 2 diabetes]
    Eberhard Standl
    ,
    Med Klin (Munich) 98:1. 2003
  37. ncbi Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus
    Naoya Hattori
    Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar, Technischen Universitat Munchen, Germany
    Eur J Nucl Med Mol Imaging 29:891-8. 2002
    ..Hydroxyl radicals may play a role in the pathogenesis of flow abnormalities in type 1 diabetes...
  38. ncbi Dysregulation of coronary microvascular reactivity in asymptomatic patients with type 2 diabetes mellitus
    Mitsuru Momose
    , Klinikum rechts der Isar, Ismaninger Strasse 22, 81675 Munich, Germany
    Eur J Nucl Med Mol Imaging 29:1675-9. 2002
    ..These data suggest a state of activation of endothelial-dependent vasodilation at baseline which appears to limit the flow response to stress conditions...
  39. ncbi Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
    Bo Ahren
    Department of Medicine, Lund University B11 BMC, SE 221 84 Lund, Sweden
    Diabetes Care 27:2874-80. 2004
    ..To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment...
  40. ncbi Telecare for patients with type 1 diabetes and inadequate glycemic control: response to Montori et al
    Eberhard Biermann
    Diabetes Care 28:228-9; author reply 229-30. 2005
  41. ncbi IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance
    Matthias R Langenfeld
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:836-43. 2004
    ....
  42. ncbi Impaired glucose tolerance, diabetes, and cardiovascular disease
    Oliver Schnell
    University of Munich and Diabetes Research Institute, Germany
    Endocr Pract 12:16-9. 2006
    ..CONCLUSION: Aggressive preventive and treatment strategies, which can include multiple interventions, are needed to minimize the potential effects of CVD in patients with diabetes or IGT...
  43. ncbi IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design
    Andreas Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Diabetes Technol Ther 7:478-86. 2005
    ..The cross-sectional IRIS-II study tried to assess the prevalence of insulin resistance and macrovascular disease in orally treated patients with Type 2 diabetes...
  44. ncbi [Diabetic patients with heart disease. Especially strict blood values are important here]
    Eberhard Standl
    MMW Fortschr Med 148:11. 2006
  45. ncbi Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    Lars Ryden
    Department of Cardiology, Karolinska University Hospital, Sweden
    Eur Heart J 28:88-136. 2007
  46. ncbi Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)
    Erland Erdmann
    Medizinische Klinik III der Universität zu Köln Kerpener Str 62, D 50937 Koln, Germany
    Diabetes Care 30:2773-8. 2007
    ..We analyzed the heart failure cases to assess the effects of treatment on morbidity and mortality after reports of serious heart failure...
  47. ncbi Guidelines for the treatment and management of new-onset diabetes after transplantation
    Alan Wilkinson
    David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Clin Transplant 19:291-8. 2005
    ....
  48. ncbi [Guidelines on diabetes, pre-diabetes, and cardiovascular diseases]
    Lars Ryden
    Rev Esp Cardiol 60:1e-64e. 2007
  49. ncbi Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
    Andreas Pfutzner
    Institute for Clinical Research and Development, IKFE GmbH, Parcusstrasse 8, 55116 Mainz, Germany
    Clin Chem Lab Med 44:556-60. 2006
    ..Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP)...
  50. ncbi [Diabetes mellitus: global strategies for control of the epidemic]
    Eberhard Standl
    Krankenpfl J 42:166. 2004
  51. ncbi An advanced approach for the assessment of gastric motor function in long-term type 1 diabetes mellitus with and without autonomic neuropathy
    Matthias Meier
    Hannover Medical School, Department of Nephrology, Germany
    Clin Auton Res 12:197-202. 2002
    ..Analyzing gastric motor function with dynamic scintigraphic techniques using condensed images is a promising clinical approach to further elucidate the mechanisms of impaired gastric motility in DM...
  52. ncbi Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention
    Jonathan E Shaw
    International Diabetes Institute, 250 Kooyong Road, Caulfield, Melbourne, VIC 3162, Australia
    Diabetes Res Clin Pract 81:2-12. 2008
    ....